Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer

Clinical Proteomics

Volumn 8, Issue 1, 2011, Pages

  Gonzalez Angulo, Ana M ^a   Hennessy, Bryan T ^a   Meric Bernstam, Funda ^a   Sahin, Aysegul ^a   Liu, Wenbin ^a   Ju, Zhenlin ^a   Carey, Mark S ^a   Myhre, Simen ^b,c   Speers, Corey ^d   Deng, Lei ^a   Broaddus, Russell ^a   Lluch, Ana ^e   Aparicio, Sam ^f   Brown, Powel ^a   Pusztai, Lajos ^a   Symmans, W Fraser ^a   Alsner, Jan ^g   Overgaard, Jens ^g   Borresen Dale, Anne Lise ^b,c   Hortobagyi, Gabriel N ^a   Coombes, Kevin R ^a   Mills, Gordon B ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Breast Cancer; Functional Proteomics; Prediction; Prognosis

Indexed keywords

DOCETAXEL; PACLITAXEL; PROTEIN ANTIBODY; TRASTUZUMAB; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESPONSE; FUNCTIONAL PROTEOMICS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NEEDLE BIOPSY; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; RECURRENCE FREE SURVIVAL; SCORING SYSTEM; SYSTEMIC THERAPY; VALIDATION PROCESS;

EID: 84858268381     PISSN: 15426416     EISSN: 15590275     Source Type: Journal    
DOI: 10.1186/1559-0275-8-11     Document Type: Article

References (36)

1. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Sorlie T, Perou CM, Tibshirani R, et al. Proc Natl Acad Sci USA 2001 98 10869 74 10.1073/pnas.191367098 11553815 (Pubitemid 32878711)
2. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Pusztai L, Ayers M, Stec J, et al. Clin Cancer Res 2003 9 2406 15 12855612 (Pubitemid 36842079)
3. A gene-expression signature as a predictor of survival in breast cancer. van de Vijver MJ, He YD, van't LJ Veer, et al. N Engl J Med 2002 347 1999 09 10.1056/NEJMoa021967 12490681 (Pubitemid 35461656)
4. Correlation between protein and mRNA abundance in yeast. Gygi SP, Rochon Y, Franza BR, Aebersold R, Mol Cell Biol 1999 19 1720 30 10022859 (Pubitemid 29098230)
5. Single cell proteomics for personalised medicine. Diks SH, Peppelenbosch MP, Trends Mol Med 2004 10 574 7 10.1016/j.molmed.2004.10.005 15567324 (Pubitemid 39573145)
6. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Yeh E, Cunningham M, Arnold H, et al. Nat Cell Biol 2004 6 308 18 10.1038/ncb1110 15048125 (Pubitemid 38584820)
7. Mechanism and function of deubiquitinating enzymes. Amerik AY, Hochstrasser M, Biochem Biophys Acta 2004 1695 189 207 10.1016/j.bbamcr.2004.10. 003 15571815 (Pubitemid 39574973)
8. Pathologic assessment of response to induction chemotherapy in breast cancer. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. Rastogi P, Anderson SJ, Bear HD, et al. J Clin Oncol 2008 10 26 78 85
9. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. Kuerer HM, Newman LA, Smith TL, et al. J Clin Oncol 1999 17 460 9 10080586 (Pubitemid 29075229)
10. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. Guarneri V, Broglio K, Kau S, et al. J Clin Oncol 2006 24 1037 44 10.1200/JCO.2005.02. 6914 16505422 (Pubitemid 46638799)
11. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. Symmans WS, Peintinger F, Hatzis C, et al. J Clin Oncol 2007 25 4414 22 10.1200/JCO.2007.10.6823 17785706 (Pubitemid 350013847)
12. Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer. Honkoop AH, Pinedo HM, De Jong JS, et al. Am J Clin Pathol 1997 107 211 8 9024070 (Pubitemid 27098173)
13. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. Overgaard M, Hansen PS, Overgaard J, et al. N Engl J Med 1997 337 949 55 10.1056/NEJM199710023371401 9395428 (Pubitemid 27425950)
14. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Overgaard M, Hansen PS, Overgaard J, et al. Lancet 1999 353 1641 8 10.1016/S0140-6736(98)09201-0 10335782 (Pubitemid 29224519)
15. An integrative genomic and proteomic analysis of PIK3CA, PTEN and AKT mutations in breast cancer. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al. Cancer Res 2008 68 6084 91 10.1158/0008-5472.CAN-07-6854 18676830
16. Validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Tibes R, Qiu Y, Lu Y, Hennessy B, Mills GB, Kornblau S, Reverse phase protein array (RPPA), Mol Cancer Ther 2006 2512 21 (Pubitemid 44650915)
17. The energy sensing LKB1-AMPK pathway regulates p27kip1 phosphorylation mediating the decision to enter autophagy or apoptosis. Liang J, Shao SH, Xu ZX, Hennessy B, Ding Z, Larrea M, et al. Nat Cell Biol 2007 9 218 24 10.1038/ncb1537 17237771 (Pubitemid 46420865)
18. Non-parametric quantification of protein lysate arrays. Hu J, He X, Baggerly KA, Coombes KR, Hennessy BT, Mills GB, Bioinformatics 2007 23 1986 94 10.1093/bioinformatics/btm283 17599930 (Pubitemid 47299840)
19. Quantified pathway inhibition as a pharmacodynamic marker facilitating optimal targeted therapy dosing: Proof of principle with the AKT inhibitor perifosine. Hennessy BT, Lu Y, Poradosu E, Liu Q, Yu S, Hall H, et al. Clin Cancer Res 2007 13 7421 31 10.1158/1078-0432.CCR-07-0760 18094426
20. A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers. Hennessy BT, Lu Y, Gonzalez-Angulo AM, Carey MS, Myhre S, Ju Z, et al. Clin Proteomics 2010 6 129 151 10.1007/s12014-010-9055-y 21691416
21. Cluster analysis and display of genome-wide expression patterns. Eisen MB, Spellman PT, Brown PO, Botstein D, Proc Natl Acad Sci USA 1998 95 14863 8 10.1073/pnas.95.25.14863 9843981 (Pubitemid 29003722)
22. Hierachical grouping to optimize an objective function. Ward JH, J Am Statist Assoc 1963 58 236 44 10.2307/2282967
23. A new look at the statistical model identification. Akaike H, IEEE Transactions on Automatic Control 1974 19 716 23 10.1109/TAC.1974.1100705
24. Appearance of quasiequivalent solutions, in a generalization of the Kruskal scale technic, to metric spaces using a Minkowski metric. Wolfrum C, Arch Psychol 1976 128 96 111
25. The measurement of observer agreement for categorical data. Landis JR, Koch GG, Biometrics 1977 33 159 74 10.2307/2529310 843571 (Pubitemid 8054849)
26. Bayesian Data Analysis. Gelman A, Carlin JB, Stern HS, Rubin DB, Boca Raton, FL. Chapman & Hall 2 2004 125 31
27. Penalized likelihood in Cox regression. Verweij PJM, Van Houwelingen JC, Stat in Med 1994 13 2427 36 10.1002/sim.4780132307
28. Generalized linear models. Hastie TJ, Pregibon D, Statistical Models in S. Wadsworth & Brooks/Cole Computer Science Series Boca Raton, Fla. Chapman & Hall/CRC, Chambers JM and Hastie TJ, 1991 195 248
29. Generalized Linear Models. Venables WN, Ripley BD, Modern Applied Statistics with S New York, NY. Springer-Verlag, Venables WN, Ripley BD, 4 2002 183 208
30. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. Ayers M, Symmans WF, Stec J, et al. J Clin Oncol 2004 22 2284 93 10.1200/JCO.2004.05.166 15136595 (Pubitemid 41115384)
31. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. Paik S, Shak S, Tang G, et al. N Engl J Med 2004 351 2817 26 10.1056/NEJMoa041588 15591335 (Pubitemid 40051905)
32. The molecular portraits of breast tumors are conserved across microarray platforms. Hu Z, Fan C, Oh DS, et al. BMC Genomics 2006 7 96 10.1186/1471-2164-7-96 16643655 (Pubitemid 43786485)
33. Concordance among gene-expression-based predictors for breast cancer. Fan C, Oh DS, Wessels L, et al. N Engl J Med 2006 355 560 9 10.1056/NEJMoa052933 16899776 (Pubitemid 44200649)
34. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Bergamaschi A, Kim YH, Wang P, et al. Genes Chromosomes Cancer 2006 45 1033 40 10.1002/gcc.20366 16897746 (Pubitemid 44435537)
35. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Neve RM, Chin K, Fridlyand J, et al. Cancer Cell 2006 10 515 27 10.1016/j.ccr.2006.10.008 17157791 (Pubitemid 44854747)
36. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. Hess KR, Anderson K, Symmans WF, et al. J Clin Oncol 2006 24 4236 44 10.1200/JCO.2006.05.6861 16896004 (Pubitemid 46630780)